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The C-type lectin E-selectin mediates the rolling of circulat-
ing leukocytes on vascular endothelial cells during the in-
ﬂammatory process. In numerous studies, the S128R
mutation of the E-selectin was associated with cardiovascu-
lar and autoimmune diseases. There is evidence that the
S128R E-selectin mutation leads to a loss in ligand speciﬁ-
city, thus increasing leukocyte recruitment. Apart from the
natural tetrasaccharide ligand sialyl Lewisx (sLex), it has
previously been proposed that non-fucosylated carbohy-
drates also bind to S128R E-selectin. To evaluate the thera-
peutic potential of the antagonism of the E-selectin mutant,
ligand speciﬁcity was reinvestigated on a molecular basis.
We determined the ligand speciﬁcity of wild-type and
S128R E-selectin in a target-based competitive assay, a
glycan array screen and cell-based binding assays under
static and ﬂow conditions. Regarding ligand-speciﬁcity, the
binding properties of S128R E-selectin were identical to
those of wt E-selectin, i.e., no mutant-speciﬁc binding of
3′-sialyl-N-acetyllactosamine, heparin, fetuin and K562
cells was observed. Additionally, the binding afﬁnities of
glycomimetic E-selectin antagonists were identical for wt
and S128R E-selectin. Overall, the previous reports on
carbohydrate ligand promiscuity of S128R E-selectin could
not be conﬁrmed.
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Introduction
In case of inﬂammation, the human body possesses a highly
sophisticated defense line. At the initial stage, the members of
the selectin family, E-, P- and L-selectin, play an important role
by recruiting leukocytes to the inﬂammatory site (Kansas
1996). However, excessive extravasation of leukocytes leads to
tissue damage being deleterious for numerous diseases with an
inﬂammatory component (Ernst and Magnani 2009). Blocking
selectins with selectin antagonists is, therefore, regarded as a
promising anti-inﬂammatory treatment.
Selectins are C-type (calcium dependent) lectins consisting
of a C-terminal cytoplasmic domain followed by a transmem-
brane region, variable numbers of short consensus repeats
(SCRs), an epidermal growth factor-like (EGF-like) domain
and an N-terminal lectin domain. Their physiological ligands
such as the P-selectin glycoprotein ligand-1 (PSGL-1) (McEver
and Cummings 1997; McEver 2001) and E-selectin ligand-1
(ESL-1) (Steegmaier et al. 1995) contain the common tetrasac-
charide epitope sialyl Lewisx (sLex, NeuNAcα2-3Galβ1-4
(Fucα1-3)GlcNAc; Figure 1A) as part of O-glycosylated glyco-
proteins. The structural analysis of E- and P-selectin soaked
with sLex revealed the central role of the L-fucose moiety,
which coordinates the Ca2+ ion with its 3- and 4-hydroxyl
groups (Somers et al. 2000).
In recent years, several case–control studies have suggested a
correlation of a single-nucleotide polymorphism (SNP) in exon
4 of the E-selectin encoding gene with an early onset, increased
susceptibility and severity of various, mainly cardiovascular
and immune diseases. These include myocardial infarction
(Yoshida et al. 2003; Stepień et al. 2011), severe recurrent
venous thromboembolism (Jilma et al. 2005, 2006) and the for-
mation of colon metastasis (Alessandro et al. 2007). The SNP
causes a mutation of serine 128 to arginine (S128R) and is
present in 10–15% of the Caucasian population (Wenzel et al.
1994). The mechanism by which the S128R mutation alters the
physiological function of E-selectin at molecular level is still
unclear, since the mutation is located in the EGF-like domain
and not in the carbohydrate recognition domain (CRD) of the
lectin. Based on the crystal structure of E-selectin (lectin and
EGF-like domain), a direct or indirect involvement of the
Ser128 in ligand binding is unlikely (Figure 1B and C) (Graves
et al. 1994; Somers et al. 2000).
All previous reports on the binding properties of the S128R
E-selectin mutant are summarized in Table I. First, Revelle et al.
showed a 2- to 3-fold increased adherence of S128R E-selectin to
HL60 cells compared with wt E-selectin (Revelle et al. 1996).
Furthermore, only S128R E-selectin was capable of binding to
heparin and to K562 cells, a cell line lacking fucosyltransferase
VII required for sLex biosynthesis (Snapp et al. 1997). They also
showed that the binding of heparin and K562 cell to the S128R
E-selectin mutant was reversed by the sLex precursor 3′-sialyl-
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N-acetyllactosamine (3′SLN, NeuNAcα2-3Galβ1-4GlcNAc) or
3′-sialyllactose (3′SL, NeuNAcα2-3Galβ1-4Glc) (Figure 1A), in-
dicating that the presence of the L-fucose moiety was no longer
required. Furthermore, Revelle et al. (1996) demonstrated that the
binding of HL60 cells (which express the sLex epitope) was abol-
ished with soluble sLex or an anti-sLex antibody for wt E-selectin,
Fig. 1. (A) The natural ligand of E-selectin is sialyl Lewisx (sLex). The proposed S128R E-selectin speciﬁc trisaccharide 3′sialyllactose lacks the L-fucose moiety.
(B) The crystal structure of the wt E-selectin/sLex complex. The residues 135–139 form interactions with the lectin domain (Lec), EGF (epidermal growth factor
like domain). (C) The side chain of the Ser128 residue forms a hydrogen bond to the backbone carbonyl of Lys152. This area is rigidiﬁed by two disulﬁde bonds
(Cys144-Cys153 and Cys127-Cys142).
Table I. Summary of the reported binding properties of the S128R E-selectin mutant
Revelle et al. (1996) Wenzel et al. (1999) Rao et al. (2002) Yoshida et al. (2003) This publication
Assay type Protein–cell Cell–cell Cell–cell Cell–cell Protein–ligand/cell
Assay conditions Static Static Flow Flow Static
wt and S128R
E-selectin constructs
Soluble Lec-EGF-CR2/IgG Full length on COS Full length on CHO Full length on
HUVEC
Soluble Lec-EGF-CR2/IgG
HL60 Higher binding of S128R than wt;
S128R not inhibited by sLex or
anti-sLex-Ab
Lower binding of
S128R than wt
Higher binding of
S128R than wt
Higher binding of
S128R than wt
Equal binding of wt and
S128R
K562 S128R binding not inhibited by
anti-sLex-Ab
n.d. Binding only of
S128R
n.d. No binding of S128R
3′SL/3′SLN Inhibition of S128R binding to
K562 and fetuin
n.d. n.d n.d. No binding of S128R
Heparin Binding only of S128R n.d. No binding of
S128R
n.d. No binding of S128R
Bovine fetuin Binding only of S128R n.d. n.d. n.d. No binding of S128R
sLex/sLea n.d. n.d. n.d. n.d. Equal binding of wt
and S128R
n.d., not determined.
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but did not affect binding of S128R E-selectin. Finally, the S128R
E-selectin mutant showed speciﬁc binding to bovine fetuin, a
glycoprotein lacking fucosylated glycans (Green et al. 1988),
further suggesting a shift in ligand speciﬁcity.
In contrast, Wenzel et al. (1999) reported cell-based assays
under static conditions that showed diminished adhesion
of HL60 cells to a COS cell monolayer bearing the S128R
E-selectin mutant compared with the wt E-selectin counterpart.
Later, Rao et al. (2002) observed that only chinese hamster
ovarian cells (CHO) cells displaying the S128R E-selectin mutant
were able to tether K562 cells under ﬂow conditions, an effect
that was not observed with wt E-selectin. However, no inhibitory
effect of heparin for S128R E-selectin as suggested by Revelle
et al. (1996) was observed. Since neuraminidase or O-sialogly
coprotein endopeptidase treatment of the K562 cells was not
deleterious for their tethering toward S128R E-selectin expres-
sing CHO cells, Neu5Ac- as well as O-linked glycoprotein-
independent binding to the S128R mutant was implied.
Finally, Yoshida et al. (2003) reported increased attachment
of HL60 cells toward human umbilical vein cells (HUVECs)
displaying S128R E-selectin compared with those displaying
wt E-selectin.
Since the S128R E-selectin polymorphism is correlated with
numerous diseases, we aimed to re-evaluate its binding speciﬁ-
city at molecular level and additionally determine the potency
of E-selectin antagonists which were originally designed for
the wt E-selectin. We used a cell-free, target-based assay, which
is routinely applied for screening of E-selectin antagonists
(Weitz-Schmidt et al. 1996; Thoma et al. 1997). In addition, in
a cell-based assay setup, we investigated the binding of HL60
and K562 cells under static and ﬂow conditions.
Results
Characterization of wt and S128R E-selectin
For the afﬁnity determination of three E-selectin antagonists and
for further functional analyses, we recombinantly expressed a wt
E-selectin construct containing the lectin domain, the EGF-like
domain and the ﬁrst two SCRs and the corresponding S128R
mutant as IgG chimera. The binding properties of the proteins
were evaluated in a cell-free, target-based assay and additionally
in a cell-based assay under static and ﬂow conditions.
The proteins were expressed in CHO cells followed by
functional puriﬁcation with the functional monoclonal anti-E-
selectin antibody 7A9 (see experimental part). The fact that the
7A9-antibody bound S128R E-selectin suggests correct folding
of the protein. The sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis showed a similar appar-
ent molecular weight of 100 kDa, suggesting equal glycosyla-
tion of the wt and the mutant E-selectin (Figure 2A). The
presence of the mutation was conﬁrmed by DNA sequencing
and at protein level by liquid chromatography-tandem mass
spectrometry analysis (data not shown).
For the evaluation of protein activity, we determined the
binding afﬁnities of the natural carbohydrate ligands sLex and
sLea to wt and S128R E-selectin as shown in Figure 2B. For wt
E-selectin, the EC50 values for biotinylated sLe
x- and sLea-poly-
acrylamide polymer (sLex- PAA, sLea-PAA) were 119.5 ± 17.1
ng/mL and 26.2 ± 1.3 ng/mL, respectively. The higher afﬁnity of
sLea compared with sLex for recombinant E-selectin has previous-
ly been reported with a comparable assay (Weitz-Schmidt et al.
1996; Thoma et al. 1997). Similar afﬁnities were also obtained
with S128R E-selectin, with EC50 values of 93.8 ± 13.1 ng/mL
for sLex-PAA and 27.2 ± 1.2 ng/mL for sLea-PAA. Using concen-
trations of the biotinylated 3′SL-polyacrylamide polymer (3′
SL-PAA) of up to 3 µg/mL, no binding was observed for both wt
and S128R E-selectin, suggesting no or very low afﬁnity. The
evaluation of higher concentrations of 3′SL-PAAwas not possible,
as the background signal increased signiﬁcantly.
SLex glycomimetics are efﬁcacious for S128R E-selectin
The binding afﬁnities of three previously reported E-selectin
antagonists for wt and S128R E-selectin are shown in Figure 2C.
In all the three of these sLex mimics, the Neu5Ac moiety has
been exchanged with (S)-cyclohexyl lactic acid. For antagonist 1
(Norman et al. 1998), GlcNAc has been replaced with (1R,2R)-
cyclohexane-1,2-diol and for antagonist 2 and 3 (Schwizer et al.
2012), with (1R,2R,3S)-3-methylcyclohexane-1,2-diol. For an-
tagonist 3, the 2-hydroxyl group of D-galactose is additionally
benzoylated. The half-maximal inhibitory concentration (IC50)
values of all three ligands were similar for the wt as well as
S128R E-selectin. In agreement with previously reported results
(Schwizer et al. 2012), the afﬁnities of compounds 2 and 3 were
approximately 4- and 14-fold higher than that of antagonist 1, re-
spectively. The absolute IC50 values obtained here are, however,
weaker than previously reported due to the presence of only two
SCR domains instead of six SCR domains, which is known to
reduce E-selectin afﬁnity (Li et al. 1994).
Evaluation of putative S128R E-selectin ligands
According to Revelle et al. (1996), bovine fetuin and heparin dir-
ectly interact with S128R E-selectin, and 3′SLN interferes with
the mutant binding to K562 cells. For the evaluation of their afﬁn-
ities (see experimental part) single concentrations of the carbohy-
drate ligands (3′SLN: 10 mM, bovine fetuin: 10 mg/mL, heparin;
10 mg/mL) were used to enable clear inhibition. As a result, the
binding of sLex-PAA to wt and S128R E-selectin was not inhib-
ited by any of the three substances (Figure 3A). In a control ex-
periment, the assay was also performed with wt P-selectin, for
which heparin is a known ligand (Nelson et al. 1993; Wang and
Geng 2003). As shown in Figure 3A, sLex-PAA binding to wt
P-selectin was completely abolished in the presence of heparin.
In addition to the target-based assays, further investigations
of the binding properties of S128R E-selectin were performed
with a cell-based assay under static and ﬂow conditions. In
the static assay, the adhesion of HL60 and K562 cells to wt
and S128R E-selectin was determined. Revelle et al. (1996)
reported that under static conditions the sLex-presenting HL60
cells adhere to both wt and mutant E-selectin, whereas the
sLex-deﬁcient K562 cells selectively bind S128R E-selectin. In
our assay, ﬂuorescently labeled HL60 and K562 cells were
allowed to bind to E-selectin coated on microtiter plates (see
Figure 3B). HL60 cells bind to both forms of E-selectin and
since the addition of the functional anti-E-selectin antibody
7A9 inhibited binding entirely, both interactions are clearly
E-selectin dependent. For the K562 cells, however, no binding
to either form of E-selectin was observed, albeit the high
number of applied cells. In the ﬂow assay, adhesion of HL60
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cells was studied at physiologic shear stress (Figure 3C). Again,
the number of initially tethered and consequently rolling cells
was similar for wt and S128R E-selectin. While at low shear
stress (1 dyne/cm2) the highest number of cells tethered and
rolled on wt and mutant E-selectin coated surfaces, decreased
tethering was observed when higher shear forces were applied
(2 and 3 dynes/cm2). At 5 dynes/cm2, tethering was entirely
abolished. Addition of EDTA completely abolished HL60 cells
from binding to both forms of E-selectin, thus conﬁrming the
calcium-dependent binding (data not shown).
Glycan array screening
To identify potential novel ligands of S128R E-selectin, a glycan
array screening was performed at the Core H facilities of the Con-
sortium for Functional Glycomics. In this analysis, 465 glycan
structures (version 4.1) were tested, including the tetrasaccharides
sLea and sLex and derivatives thereof such as 3′SLN, Lea and
Lex. For comparison, wt and S128R E-selectin were analyzed in
parallel. Binding of the E-selectin constructs was detected with
Alexa Fluor® 488 labeled anti-IgG antibody and was quantiﬁed
by measuring ﬂuorescence intensities as shown in Figure 4.
The results clearly indicate that both proteins preferentially
bind to glycan structures bearing sLea and sLex, thus conﬁrm-
ing the result of the competitive binding assays. In addition,
binding to 3-sulfated Lewisa and Lewisx was also observed for
both E-selectin constructs. Finally, the S128R mutant did not
exhibit any afﬁnity for 3′SLN or any other non-fucosylated
glycan. For both proteins, the ten best binding glycan structures
contain a fucose moiety. This result underlines the importance
of the fucose moiety for the binding of wt E-selectin and the
corresponding mutant S128R E-selectin.
Discussion
A SNP of E-selectin in which the serine residue at position 128
is substituted by arginine was shown to correlate with various
cardiovascular and immune diseases (Yoshida et al. 2003;
Fig. 2. (A) SDS-PAGE analysis of recombinant wt and S128R E-selectin puriﬁed by afﬁnity chromatography on a 7A9-Sepharose column as described in the
Materials and methods section. M, molecular weight marker. (B) Determination of the EC50 values for sLe
x-, sLea- and 3′SL-PAAwith wt E-selectin (B, upper
panel) and S128R mutant (B, lower panel). For this assay microtiter plates were coated overnight with either wt or S128R E-selectin (3 µg/mL), blocked with BSA
(2%) and incubated with increasing concentrations of sLex-PAA. The bound polymer was detected by colorimetric reaction at 415 nm. The assay was repeated three
times, each in duplicate as described in the Materials and methods section. (C) Competitive binding assay for the determination of IC50 for antagonists 1-3 with wt
and S128R E-selectin. The assay was performed as described in the Materials and methods section.
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Jilma et al. 2006; Alessandro et al. 2007). The mutation is
located in the EGF-like domain of E-selectin, which is neces-
sary for, but not directly involved in, ligand binding (Erbe et al.
1992). Revelle et al. (1996) reported that the regular physio-
logical E-selectin ligand, the tetrasaccharide sLex was no
longer required for S128R E-selectin to interact with HL60 and
K562 cells.
In competition assays with K562 cells or heparin, 3′SL and
3′SLN were identiﬁed as ligands for S128R E-selectin.
Furthermore, the glycoproteins heparin and bovine fetuin were
shown to interact only with S128R E-selectin and not with wt
E-selectin. Interestingly, the E-selectin R84A mutation, which
is located adjacent to the carbohydrate-binding site, showed
identical binding behavior as the S128R mutant. Binding of
E-selectin-R84A to fetuin, however, was not observed in a pre-
vious publication, notably with the identical assay (Kogan et al.
1995). In contrast, Rao et al. (2002) reported that heparin did
not inhibit S128R E-selectin binding to K562 cells. As stated
above, the adverse effects of the S128R mutation were
investigated in a number of case–control studies for a variety of
diseases, indicating that the loss of ligand speciﬁcity is possibly
correlated with an increased leukocyte recruitment which in
turn leads to pathophysiological situations.
Selectin antagonists have unequivocally been shown to inter-
fere with excessive recruitment of leukocytes upon inﬂammation
in vivo (Mulligan et al. 1993; Norman et al. 1998; Ridger et al.
2005). For the development of such antagonists, functional and
structural information on the target protein are a prerequisite. For
this purpose and due to the controversial reports on the binding
properties of the S128R mutant, we decided to express the
S128R mutant and the corresponding wt E-selectin as secreted
IgG forms. Using cell-free target-based and cell-based binding
assays, we assessed the binding properties of S128R E-selectin
in comparison with the wild-type (wt). For wt and mutant
E-selectin, no signiﬁcant difference in the afﬁnity for sLea and
sLex was observed, indicating that the carbohydrate-binding site
of the E-selectin mutant is not altered.
Fig. 3. Evaluation of the binding of 3′SLN (10 mM), heparin (Hep) (10 mg/mL) and bovine fetuin (Fet) (10 mg/mL) to wt E-selectin and S128R mutant (A).
Microtiter plates were coated with either wt or S128R E-selectin (3 µg/mL), blocked with BSA (2%) and incubated with a ﬁxed concentration of sLex-PAA (20 ng/
mL), either in the presence or in the absence of Hep and Fet. As positive control wt P-selectin was co-incubated with sLex-PAA (20 ng/mL) and heparin (10 mg/mL).
(B) Cell-based static binding assay with HL60 and K562 cell lines. Microtiter plates were coated with either wt or S128R E-selectin (10 µg/mL), blocked with BSA
(2%) and incubated with the ﬂuorescently labeled cells (2 × 105 cells/well), in the presence or absence of anti-E-selectin antibody 7A9 (20 µg/mL). Bound cells
were measured by ﬂuorescence measurements at 492 nm excitation and 517 nm emission wavelengths. The assay was repeated twice, each in duplicate as described
in the Materials and methods section. (C) Cell-based ﬂow binding assay with HL60 cells at physiological shear stress. Flow chambers were coated with protein
A (50 µg/mL) and subsequently with wt or S128R E-selectin (50 µg/mL). The HL60 cells (1 × 106 cells/mL) were perfused at given shear stress (1–5 dynes/cm2).
Cells were counted after 10 min at three points along the ﬂow chamber. The error bars correspond to the standard error of the mean of the three points.
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To investigate a potential treatment of patients carrying the
S128R E-selectin polymorphism, binding afﬁnities of three
E-selectin antagonists were determined (Figure 2C). We dem-
onstrate that regardless of the S128R mutation, binding afﬁn-
ities for all antagonists were similar when compared with wt
E-selectin. This further conﬁrmed that carbohydrate-binding
site of S128R E-selectin was intact and suggests a possible ap-
plication of such sLex mimics in the treatment of affected
patients. Regarding the speciﬁcity of S128R E-selectin, direct
binding of the 3′SL polymer was not observed even at high
concentrations. To further evaluate the promoted speciﬁc
ligands for S128R E-selectin, inhibition assays with sLex
Fig. 4. Glycan array screening (version 4.1) of wt and S128R E-selectin. Binding was detected by a second incubation with Alexa Fluor® labeled anti-IgG antibody
as described in the Materials and methods section. The values of the RFUs are given the average of 6 measurements of which the lowest and highest values were
removed.
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polymer in competition with the 3′SLN trisaccharide, heparin
and bovine fetuin were performed. Even at high concentrations,
none of these three compounds showed inhibition of the sLex
polymer binding to S128R E-selectin (Figure 3A). These results
suggest similar binding phenotypes of wt and S128R E-selectin.
Finally, to investigate the binding of S128R E-selectin to leuko-
cytes, we performed cell-based assays (Figure 3B and C). The
sLex bearing HL60 cell line bound wt and S128R E-selectin to
the same degree under static and physiological ﬂow conditions
and in an E-selectin dependent manner. Again, no difference
in binding speciﬁcity was observed for S128R E-selectin.
Furthermore, unlike previously reported, no speciﬁc binding
of K562 cells was measured. Therefore, no interaction between
S128R E-selectin and an unknown carbohydrate or non-
carbohydrate ligand on K562 occurred. Finally, to characterize
the binding phenotype with another cell-free assay, a glycan
array screening was performed at the Consortium for Functional
Glycomics (Figure 4). The binding of wt and S128R E-selectin
to 465 different mammalian glycan structures was evaluated.
The results conﬁrmed the similar binding proﬁles for wt and
S128R E-selectin. The 10 best binding glycan structures all con-
tained a fucose moiety. The RFU values of glycans lacking the
fucose moiety such as 3′SLN showed signals on background
level for both proteins. Additionally, no speciﬁc ligand for the
S128R E-selectin mutant was detected, and thus, its binding
properties do not differ from those of the wt. As in the EC50
determinations of sLea and sLex, an augmented binding of sLea
over sLex was also observed which is reﬂected by the higher
RFU values for sLea. Although high E-selectin concentrations
(1 mg/mL) were applied for the glycan array, the resulting RFU
values were rather low. This was most likely due to the low afﬁn-
ity of E-selectin for its tetrasaccharide ligands (Schwizer et al.
2012). The reason why S128R E-selectin showed eightfold
lower maximal RFU values compared with wt E-selectin is not
clear, since in the polymer-based activity assays, the afﬁnity
(EC50) of both proteins for sLe
x- and sLea-PAAwere comparable
(equal maximal OD415nm values). However, glycan array screen-
ings provide for qualitative and not quantitative measurements.
Our results suggest similar binding speciﬁcities of wt and
S128R E-selectin under static and ﬂow conditions. This is to be
expected from a visual inspection of the E-selectin crystal struc-
ture in complex with sLex (Somers et al. 2000). It was shown
that only the amino acids 135–139 from the EGF-like domain
form a direct contact with the lectin domain by hydrogen
bonding and van der Waals interactions (Graves et al. 1994).
The distance between the Ser128 Cα atom and Ca2+ in the
binding site is 43 Å. The Ser128 side chain forms a hydrogen-
bond with the backbone carbonyl of Lys152, an interaction
found in all selectin crystal structures. This hydrogen bond
would be lost in case of the S128R mutation. The fact that the
amino acid sequence Ser126-Cys127-Ser128 is conserved in all
the three selectins and throughout several species implies that
this region is indeed important for the proper function of the
selectins. However, the region surrounding the mutation is ri-
gidiﬁed by three disulﬁde bonds (Cys122–Cys133, Cys127–
Cys142 and Cys144–Cys153) within a 10 Å radius of Ser128
Cα atom (Figure 1C).
In conclusion, as the S128R E-selectin displayed unaltered
binding speciﬁcity under static and ﬂow conditions as wt
E-selectin, we conclude that glycomimetic E-selectin antagonists
are also effective antagonists of the mutant. According to our
studies, the reported correlation of a SNP in the E-selectin en-
coding gene with an increased susceptibility and severity of
various, mainly cardiovascular and immune, diseases is there-
fore not related to altered binding properties of wt and mutant
E-selectin. Further investigations, e.g., structural and biophysic-
al protein characterization, as well as functional in vivo assays
are necessary to shed light on possible therapeutic opportunities
based on the S128R E-selectin mutant.
Materials and methods
Materials and reagents
The E-selectin primers lec-fw (5′-GGCC GAATTC GTG GTC
TTA CAA CAC CTC CAC GGA A-3′) and cr2_rev (5′-GGCC
GATATC GAA GCT TTA CAC GTT GGC TTC TCG TT-3′)
containing the restriction sites EcoRI and EcoRV (underlined),
respectively, and the mutation primers egf_s128r_fw (5′-AAT
ACATCC TGC AGA GGC CAC GGT-3′) and egf_s128r_rev
(5′-ACC GTG GCC TCT GCA GGA TGT ATT-3′) were pur-
chased from Microsynth (Balgach, Switzerland). The restriction
enzymes EcoRI and EcoRVand the glycosidase PNGaseF were
obtained from New England BioLabs (Allschwil, Switzerland).
The pFUSE-hIgG2-Fc2 expression vector and the antibiotic
Zeocin™ were purchased from Invivogen (Toulouse, France).
Tissue culture ﬂasks and MaxiSorp™ 96-well microtiter plates
were from Nunc (Roskilde, Denmark). Ham’s Nutrient Mixture
F-12 medium, Roswell Park Memorial Institute (RPMI-15)
medium, fetal calf serum (FCS) and the horseradish peroxidase
substrate 2,2′-azino-di(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS) were purchased from Invitrogen (Lucerne, Switzer-
land). Penicillin (10,000 U/mL)/streptomycin (10 mg/mL),
cyanogen bromide-activated-Sepharose® 4B, bovine fetuin and
heparin sodium salt were obtained from Sigma-Aldrich (Basel,
Switzerland). The FuGENE® HD transfection reagent and the
streptavidin-peroxidase (streptavidin-POD)were purchased from
Roche Applied Science (Rotkreuz, Switzerland). Amicon®
ultraﬁltration tubes (50 kDa cut-off) were obtained from
Millipore (Zug, Switzerland). The ion exchange column
UnoQ6 was purchased from Bio-Rad (Reinach BL, Switzer-
land). Protein A-Sepharose® was obtained from BioVision
(Mountain View, CA). Protein G-Sepharose® was purchased
from Amersham Pharmacia (GE Healthcare, Pistcataway, NJ).
3-SL, sLex- and sLea-polyacrylamide (PAA)-biotin were fromGly-
coTech (Gaithersburg, MD). The Alexa Fluor® 488 labeled
anti-human-IgG(Fc) antibody and the Microscanarray XL4000
scanner were from Invitrogen (Carlsbad, CA) and PerkinElmer
Life Sciences (Waltham, MA), respectively. Trypsin sequen-
cing grade was obtained from Promega (Dübendorf, Switzer-
land). The trapping 300SB C-18 column (0.3 × 50 mm) was
purchased from Agilent Technologies (Basel, Switzerland), the
Magic 300 Å C18 reverse-phase material (5 µm particle size)
from Michrom Bioresources, Inc. (Auburn, CA), the Orbitrap
FT hybrid instrument from Thermo Finnigan (San Jose, CA)
and the Rheos 2200 pump from (Flux Instruments, Basel,
Switzerland). The cell line HL60 was purchased from LGC
Standards (Molsheim, France) and K562 cells from the
German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). The BioFlux™ system was
purchased from Fluxion (San Francisco, CA).
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Molecular cloning
Genomic DNA from wild-type human E-selectin [Lec-EGF-
CR6/hIgG1(Fc)] expressing CHO-K1 cells (Schefﬂer et al. 1995)
was used for polymerase chain reaction (PCR) ampliﬁcation of
the cDNA encoding for the human E-selectin lectin domain (bp
1–360), the EGF-like domain (bp 361–471) and the ﬁrst two con-
sensus repeat domains (bp 472–840). The forward primer lec_fw
and the reverse primer cr2_rev containing EcoRI and EcoRV re-
striction sites were used. The restricted insert was ligated into the
corresponding cloning site of the pFUSE-hIgG2-Fc2 expres-
sion vector. The resulting construct containing the N-terminal
interleukine-2 secretion signal and the Fc part of human IgG2
at C-terminus was transformed into chemocompetent Escherichia
coli DH5α. After single clone selection and DNA-minipreparation,
the correctness of the construct was conﬁrmed by DNA double-
strand sequencing (Microsynth, Balgach, Switzerland).
Site-directed mutagenesis was employed for the thymine-
to-adenine substitution at cDNA position 384, shifting the ex-
pression from a serine to an arginine at amino acid position 128.
The standard overlap extension PCR method was used (Ho et al.
1989). In a ﬁrst step, two overlapping DNA fragments were gen-
erated separately, using wild-type E-selectin cDNA as template.
The ﬁrst fragment was ampliﬁed with the lec_fw primer and the
internal reverse primer egf_s128r_rev and the second fragment
was ampliﬁed using cr2_rev and the internal forward primer
egf_s128r_fw. The two internal primers contained a mismatch
for the site-directed base substitution. In a second step, both
overlapping DNA fragments were elongated to the full-length
insert, containing the single point mutation. The cloning into the
pFUSE-hIgG2-Fc2 expression vector and sequence veriﬁcation
were performed as described above for the wt construct.
Cell transfection and expression of wt E-selectin,
wt P-selectin and S128R E-selectin
CHO-K1 cells (American Type Culture Collection No.
CCL-61™) were cultivated in tissue culture ﬂasks in Ham’s
Nutrient Mixture F-12 medium supplemented with 2 mM
L-glutamine, 10% (v/v) FCS, 100 U/mL penicillin and 100 µg/
mL streptomycin. The cells were transfected with either the wt or
the S128R construct using the FuGENE® HD transfection
reagent according to the instructions of the supplier (Roche).
The selection of stably transfected CHO-K1 cells was achieved
by treatment with 500 µg/mL Zeocin™ and single clones
were obtained by limiting dilution. Culture medium containing
the secreted E-selectin [Lec-EGF-CR2/hIgG2(Fc)] chimera was
harvested weekly and sterile ﬁltered (0.22 µm). The medium was
used immediately for protein puriﬁcation or stored at −20°C.
For control experiments P-selectin [Lec-EGF-CR6/hIgG1
(Fc)] wt expressed in CHO-K1 cells was used (Fritz et al. 1998).
Expression and puriﬁcation of anti-E-selectin antibody 7A9
Mouse hybridoma cells expressing the mouse monoclonal anti-
E-selectin antibody 7A9 (American Type Culture Collection No.
HB-10135™) were cultivated in RPMI-15 medium supplemen-
ted with 15% (v/v) FCS, 100 U/mL penicillin and 100 µg/mL
streptomycin. Antibodies were puriﬁed from the culture medium
by protein G-Sepharose®. The column was attached to a fast
protein liquid chromatography apparatus (Bio-Rad, Reinach BL,
Switzerland) and equilibrated with loading buffer (50 mM Tris–
HCl (pH 7.6), 150 mM NaCl and 0.05% v/v Tween-20). The
culture medium was ﬁltrated (0.22 µm) diluted with loading
buffer and then loaded onto the protein G-Sepharose® column
followed by two washing steps, ﬁrst with loading buffer and then
with washing buffer (5 mM NH4OAc, pH 5.0). The protein was
ﬁnally eluted with elution buffer (0.5 M NH4OAc, pH 3.4) and
the eluate was immediately neutralized to pH 7–7.5 with a 2.5 M
Tris solution. The protein concentration was determined by high-
performance liquid chromatography (HPLC) (Mesch et al.
2012). Approximately 5 mg of puriﬁed 7A9 antibody were
coupled to 1 mL of cyanogen bromide-activated-Sepharose® 4B
according to the manufacturer’s protocol.
Puriﬁcation of wt E-selectin, wt P-selectin and S128R
E-selectin
The culture medium containing E-selectin was diluted (1:1, v/v)
with loading buffer, ﬁltrated (0.22 µm) and puriﬁed with the
7A9-Sepharose® column using the same protocol and buffers as
for the puriﬁcation of the 7A9 antibody (see above). The puriﬁed
protein was concentrated by ultraﬁltration (50 kDa cut-off).
P-selectin was puriﬁed in two steps. The ﬁrst step was per-
formed on a protein A-Sepharose® column using the same pro-
cedure and buffers as described above. The second step was
performed with anion exchange chromatography using a
UnoQ6 column and the buffer A (20 mM Tris–HCl, pH 7.4)
for column equilibration and loading and buffer B (20 mM
Tris–HCl, pH 7.4, 1 M NaCl) for protein elution.
Protein purity was conﬁrmed by SDS-PAGE analysis fol-
lowed by Coomassie Brilliant Blue G-250 staining. The protein
concentration was determined by HPLC as previously reported
(Mesch et al. 2012).
Activity binding assay
Biotinylated sLex-, sLea- and 3′SL-polyacrylamide polymers
(sLex-PAA, sLea-PAA and 3′SL-PAA, purchased from Glyco-
Tech, Gaithersburg, MD 20879) were coupled to streptavidin-
β-peroxidase (POD) by incubation of 20 µL (100 µg/mL)
polymer, 80 µL (500 U/mL streptavidin-POD conjugate), 10 µL
FCS and 80 µL assay buffer (20 mM HEPES pH 7.4, 150 mM
NaCl, and 10 mM CaCl2) for 2 h at 37°C. The complexes were
stable for several weeks when stored at 4°C.
MaxiSorp™ 96-well microtiter plates were coated with
100 µL/well of wt or S128R E-selectin at 3 µg/mL in assay
buffer overnight at 4°C in a humidiﬁed chamber. Control wells
were coated with assay buffer without protein for subsequent
background signal subtraction. The wells were washed three
times with 150 µL/well of assay buffer and blocked with 150 µL/
well of 3% w/v bovine serum albumin (BSA) in assay buffer for
3 h at 4°C. The wells were then washed three times with 150 µL/
well assay buffer before adding 100 µL/well of a serial dilution
(0–3 µg/mL) of a sLex-, sLea- or 3′SL-PAA solution. Each con-
centration was applied in duplicate. After incubation for 3 h at
25°C and 250 rpm, the wells were carefully washed with 150 µL/
well assay buffer. Carbohydrate-PAA binding was detected by
addition of 100 µL/well of ABTS-substrate. The colorimetric re-
action was allowed to develop for 10 min and then stopped by
the addition of 2% aqueous oxalic acid before the optical density
(OD) was measured at 415 nm on a microplate reader. The
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OD415 nm values were background subtracted and the EC50
values were calculated using the Prism software (GraphPad
Software, Inc., La Jolla). The assays were repeated three times on
separate days. The EC50 value deﬁnes the glycopolymer concen-
tration corresponding to 50% of the maximum binding to the
protein.
Competitive binding assay
For the evaluation of the proposed ligands for S128R E-selectin
and the afﬁnity measurements of the sLex mimics, polyacryl-
amide polymer-based competitive binding assay was performed.
The trisaccharide 3′-sialyl-N-acetyllactosamine (3′SLN) was
synthesized in-house as reported in the Supplementary data.
Antagonists 1-3 were prepared as previously described (Schwi-
zer et al. 2012). MaxiSorp™ 96-well microtiter plates were
coated with a solution of E- or P-selectin (3 µg/mL, 100 µL/
well) and blocked for 3 h with 150 µL/well of BSA (3%, w/v).
The wells were subsequently co-incubated with 50 µL of
sLex-PAA (40 ng/mL) and 50 µL of 3′SLN (10 mM ﬁnal con-
centration), bovine fetuin (10 mg/mL) or heparin sodium salt
(10 mg/mL). Inhibition of sLex-PAA binding to wt P-selectin by
heparin sodium salt served as positive control. For compounds
1-3, 25 µL of serial dilutions were mixed with 25 µL of
sLea-PAA polymer (40 ng/mL). All other assay steps were per-
formed similar to the activity binding assay. For 3′SLN, the
assay was repeated twice on separate days and for bovine fetuin
and heparin three times on separate days. The sLex mimics were
tested a single time in duplicate. IC50 values were calculated
using the Prism software. The IC50 deﬁnes the molar concentra-
tion of the test compound that reduces the maximal speciﬁc
binding of sLex/a-PAA to E/P-selectin by 50%.
Cell-based static assay
The protein coating, washing and blocking steps of the cell-based
binding assay were performed similar to the activity binding
assay, with an increase in wt or S128R E-selectin concentration
to 10 µg/mL. HL60 and K562 cells were cultivated in suspension
in RPMI 1640 culture medium supplemented with 10% FCS, 2
mM L-glutamine, 10% (v/v) FCS, 100 U/mL penicillin and
100 µg/mL streptomycin. The cell suspension was harvested at
5 × 105–1 × 106 cells/mL by centrifugation at 1500 rpm and 4°C.
The cells were washed twice with PBS, resuspended to 1 × 106
cells/mL and labeled with 5 µM carboxyﬂuorescein succinimidyl
ester) for 8 min at room temperature. The reaction was stopped
with FCS (2%, v/v) and the cells were washed twice with
assay buffer containing FCS (2%, v/v). Final concentrations of
2 × 105 cells/well and 20 µg/mL 7A9 antibody were used. After
incubation for 1 h at 37°C and 250 rpm, the wells were washed
three times with assay buffer. Fluorescent intensities were mea-
sured at 492 nm excitation and 517 nm emission with a ﬂuores-
cence plate reader. The cell-based assays were performed in
duplicate and repeated twice on separate days. Cell viability was
>95% at all times as judged by trypan blue staining.
Cell-based ﬂow assay
Flow chamber assays were performed with a BioFlux™
system. The ﬂow chambers were coated over night at 4°C with
50 µg/mL soluble protein A in bicarbonate buffer (pH 9.6).
After washing with assay buffer, the chambers were perfused
with wt or S128R E-selectin (50 µg/mL) and incubated for 2 h
at 4°C. The chambers were subsequently blocked with 2% w/v
BSA in assay buffer. HL60 cells were prepared as described
above, resuspended to 1 × 106 cells/mL and perfused at physio-
logical shear forces between 1 and 5 dynes/cm2. Rolling cells
were determined at three points along the chamber after 10 min
perfusion with a Nikon inverted-stage phase-contrast micro-
scope with 20 × magniﬁcation. Shutter speed was set according
to shear stress for correct distinction of adherent and free
ﬂowing cells.
Glycan array screening
The glycan array screening (version 4.1) was performed at the
Core H facilities of the Consortium for Functional Glycomics
as previously described (Blixt et al. 2004). Brieﬂy, the wt
and S128R E-selectin samples were diluted to 1 mg/mL in
Tris-buffer [20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 2 mM
CaCl2, 2 mM MgCl2] supplemented with 0.05% Tween 20
and 1% BSA. An aliquot of 70 µL was applied to the slides
containing the covalently linked glycans, each glycan in repli-
cate of six. The slides were coverslipped and incubated in a
humidiﬁed chamber protected from light for 1 h at room tem-
perature and subsequently incubated with Alexa Fluor® 488
labeled anti-human-IgG(Fc) antibody at a concentration of 5
µg/mL in Tris-buffer. After washing and drying the slides, the
ﬂuorescence was measured with the Microscanarray XL4000
scanner. The relative ﬂuorescence units (RFUs) were then cal-
culated as the average of the six replicates of each glycan
structure, of which the lowest and the highest values were
ignored.
Supplementary data
Supplementary data for this article is available online at http://
glycob.oxfordjournals.org/.
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